Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis

Mary Beth Nierengarten  |  Issue: June 2017  |  June 14, 2017

Stem cells in a fluid are being transferred for study.

Stem cells in a fluid are being transferred for study.
CI Photos/shutterstock.com

Rheumatologists now have another treatment option to offer their patients with one of, if not the most, difficult autoimmune diseases to treat. New data add to the growing evidence of the safety and benefit of stem cell transplantation for patients with systemic sclerosis with internal organ involvement.

New results of the Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial show that patients with systemic sclerosis with lung involvement who underwent myeloablative autologous hematopoietic stem cell transplantation (HSCT) had superior long-term outcomes compared with patients treated with monthly intravenous cyclophosphamide (CYC).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Reporting on the results of the trial at the 2016 ACR/ARHP Annual Meeting, Keith Sullivan, MD, James B. Wyngaarden Professor of Medicine in the Division of Cellular Therapy, Duke University Medical Center, Durham, N.C., says the results suggest it’s time to consider this treatment approach for select patients with systemic sclerosis with early, severe internal organ involvement.1

“Our job is to fully inform the patient and caregiver of the results of randomized clinical trials and the usefulness of the procedure,” he says, emphasizing that rheumatologists now have a treatment option for this difficult and often fatal disease that patients should know about.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“I’m not trying to oversell this,” he says, “I am trying to have colleagues see things through patients’ eyes, because if the patient never gets referred for a consultation with a transplant physician, this treatment will never be an option for them.”

What the Data Show

Results of the multicenter SCOT trial (currently in peer review for publication) support and expand the evidence for the superiority of stem cell transplantation compared with pulse CYC for select patients with systemic sclerosis, previously reported in the Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, and to a more limited degree (because of shorter follow-up of a smaller patient cohort), in the American Scleroderma Stem Cell vs. Immune Suppression Trial (ASSIST).2

In the SCOT trial (sponsored by the National Institutes of Health, National Institute of Allergy and Infectious Diseases), 75 patients with diffuse cutaneous systemic sclerosis and progressive lung or renal involvement were randomized to CYC (750 mg/m2/month) infused over one year (n=39) or myeloablative HSCT (n=36). Unlike the ASTIS and ASSIST trials in which patients were given nonmyeloablative high-dose CYC for both preparative conditioning and stem cell mobilization, the SCOT trial used a lower dose of pre-transplant CYC and employed total body irradiation conditioning to eliminate all autoreactive immune cells prior to stem cell rescue.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsResearch RheumSystemic Sclerosis Tagged with:Clinicaloutcomepatient careResearchrheumatologistrheumatologySclerodermastem cell transplantationSystemic sclerosistherapyTreatment

Related Articles
    HSCT for Severe Autoimmune Diseases

    HSCT for Severe Autoimmune Diseases

    August 14, 2017

    Despite the innovations of new biologics and disease-modifying anti-rheumatic drugs, a large unmet need remains for patients with rheumatic autoimmune disease. Treatment remains limited for many conditions, including for conditions with a dim prognosis, such as systemic sclerosis.1 One promising treatment avenue is hematopoietic stem-cell transplantation (HSCT). Here, we provide background on HSCT for severe…

    Cellular Therapy of Autoimmune Disease

    November 1, 2008

    Is a novel treatment breakthrough on the horizon?

    Stem Cell Transplantation Benefits Patients with Scleroderma

    February 26, 2018

    A recently published study gives new insight into an innovative approach to treating patients with severe scleroderma and internal organ involvement. During the six-year study, researchers demonstrated the durability of the beneficial effects of stem cell transplantation in this patient population. Their data also suggest the treatment has the potential to renormalize the autoreactive immune system…

    Progress Continues in Systemic Sclerosis

    March 1, 2010

    Advances in genetics and potential therapies shed new light on the disease

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences